13:
Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Pressel SL, Davis BR, Wright JT, Geraci TS, Kingry C, Ford CE, Piller LB, Bettencourt J, Kimmel B, Lusk C, Parks H, Simpson LM, Nwachuku C, Furberg CD; ALLHAT Collaborative Research Group.
Control Clin Trials. 2001 Feb;22(1):29-41.
PMID: 11165421 [PubMed - indexed for MEDLINE]
Related Articles
16:
Telemedicine for the Medicare population: pediatric, obstetric, and clinician-indirect home interventions.
Hersh WR, Wallace JA, Patterson PK, Shapiro SE, Kraemer DF, Eilers GM, Chan BK, Greenlick MR, Helfand M.
Evid Rep Technol Assess (Summ). 2001 Aug;(24 Suppl):1-32.
PMID: 11569328 [PubMed - indexed for MEDLINE]
Related Articles
19:
Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.
Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM.
Am J Hypertens. 1996 Apr;9(4 Pt 1):342-60.
PMID: 8722437 [PubMed - indexed for MEDLINE]
Related Articles